youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
ZTS:NYSE
Zoetis Inc
$83.18
arrow_upward
+4.34%(+3.46) 1D
$83.18
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:04 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZTS...
Open
$80.15
High
$83.22
Low
$79.89
Mkt. cap
34.37B
Avg. vol.
3.90M
Volume
5.42M
Dividend
2.55%
Quarterly dividend
$0.53
Ex-dividend date
Oct 30, 2026
P/E ratio
13.68
52-wk high
$144.83
52-wk low
$68.77
EPS
$6.08
Beta
0.74
Shares outstanding
413.22M
No. of employees
14K
Open
$80.15
High
$83.22
Low
$79.89
Mkt. cap
34.37B
Avg. vol.
3.90M
Volume
5.42M
Dividend
2.55%
Quarterly dividend
$0.53
Ex-dividend date
Oct 30, 2026
P/E ratio
13.68
52-wk high
$144.83
52-wk low
$68.77
EPS
$6.08
Beta
0.74
Shares outstanding
413.22M
No. of employees
14K
News stories
From web sources and news partners
GuruFocus
·
8 hours ago
Zoetis Inc (ZTS) Stock Up 4.3% and Still Undervalued -- GF Score: 73/100
MarketWatch
·
9 hours ago
Zoetis Inc. stock outperforms competitors on strong trading day
Zacks
·
16 hours ago
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ChartMill
·
20 hours ago
Zoetis (NYSE:ZTS) Dividend Quality Backed by Strong Profitability and Health Ratings
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.
In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14.5K
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, United States
SectorPharmaceutical industry
Websitezoetis.com